All In Biotech

Free tool

FAERS Monitor: Benlysta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761043 or its brand name (Benlysta, Belimumab). Reports on generic versions are filed under their own applications.

Reports

32,030

Serious

13,657

43% of reports

Hospitalization

4,745

Death reported

907

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue5,154
  • systemic lupus erythematosus3,979
  • fatigue2,095
  • drug ineffective1,857
  • pain1,776
  • wrong technique in device usage process1,635
  • headache1,593
  • nausea1,526
  • malaise1,425
  • product complaint1,411
  • injection site pain1,388
  • arthralgia1,380
  • off label use1,118
  • accidental exposure to product1,058
  • exposure via skin contact1,029

Reports by year received

View as table
YearReports
2011132
2012893
2013711
2014656
20151,107
2016802
20171,033
20182,166
20192,969
20202,195
20212,402
20222,867
20233,400
20243,817
20255,198
20261,682

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,022,129 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
systemic lupus erythematosusSignal3,97982.880.2285,858
product complaintSignal1,41138.736.748,910
exposure via skin contactSignal1,02927.125.524,855
wrong technique in device usage processSignal1,63523.822.734,490
product dose omission issueSignal5,15411.711.450,225
accidental exposure to productSignal1,0586.86.45,201
injection site painSignal1,3883.02.81,843
arthralgiaSignal1,3802.22.1899
malaiseSignal1,4252.12.0877
pain1,7761.91.8778
fatigue2,0951.81.7725
headache1,5931.71.6440
nausea1,5261.31.289
drug ineffective1,8570.90.912
off label use1,1180.80.836

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.